ReviewClinical lymphoma & myeloma2009
Hodgkin lymphoma: an update on its biology with new insights into classification.
Review in Clinical lymphoma & myeloma, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis.BMC cancer · 2019Pooled it
- A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus.Nature communications · 2014Pooled it
- A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32.Blood · 2012Pooled it
- Quantity Does Not Matter: Number, Ratio, or Grouping of Hodgkin/Reed-Sternberg Cells Does Not Affect Prognosis in Patients with Classic Hodgkin Lymphoma.Medicina (Kaunas, Lithuania) · 2026Article
- Unfolding the enigma of familial Hodgkin lymphoma: Current insights.World journal of clinical cases · 2026Review
- Review
- Cytotoxic T-lymphocyte-associated 4 protein expression is associated with a high international prognostic score in advanced-stage classical Hodgkin lymphoma.BMC research notes · 2024Article
- Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.Blood · 2023Article
- The Medium Obtained from the Culture of Hodgkin Lymphoma Cells Affects the Biophysical Characteristics of a Fibroblast Cell Model.Bioengineering (Basel, Switzerland) · 2023Article
- Circulating tumor DNA in Hodgkin lymphoma.Annals of hematology · 2022Review
- Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.Cancers · 2022Article
- Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.Diagnostics (Basel, Switzerland) · 2022Review
- Hodgkin Lymphoma in People Living with HIV.Cancers · 2021Review
- Spectrum of common Hodgkin lymphoma and non-Hodgkin lymphomas subtypes in Zambia: a 3-year records review.Journal of health, population, and nutrition · 2021Article
- Diagnostic dilemma of Hodgkin's lymphoma versus tuberculosis: a case report and review of the literature.Journal of medical case reports · 2021Review
- A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types.Molecular biology reports · 2021Review
- An Autopsy Case of an Elderly Patient with Classic Hodgkin Lymphoma Presenting with a Plethora of Clinical Symptoms and Signs.The American journal of case reports · 2020Article
- Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease.Blood advances · 2020Article
- Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment.Cancers · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In the past few years, there has been a greater understanding of the spectrum and biology of Hodgkin lymphoma (HL). In standard texts, HL is classified as 2 distinct entities, namely nodular lymphocyte-predominant HL and classical HL (CHL). However, recent evidence suggests that CHL is not a single disease. Although the mixed cellularity and lymphocyte-depleted subtypes might be part of a biologic continuum, the nodular sclerosis subtype has a distinct epidemiology, clinical presentation, and histology. Nodular sclerosis HL might also be related to primary mediastinal B-cell lymphoma and mediastinal gray-zone lymphomas. We present an update on the pathobiology of HL and discuss these biologic and clinical differences in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.